Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (29)
Luisa Gracio Ferreira Sartori, Bruno Monteiro Nunes, Daniela Farah, Leticia Maria de Oliveira, Claudia Cristina Takano Novoa, Marair Gracio Ferreira Sartori & Marcelo Cunio Machado Fonseca. (2023) Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis. Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics 45:06, pages 337-346.
Crossref
Crossref
Alsayed Saad Abdelaziz, Nashaat Mohammed Salama & Ayman Mohammed Ghoneem. (2022) Mirabegron vs. solifenacin in control of endoscopically inserted ureteral stent-related symptoms. World Journal of Urology 40:8, pages 2113-2119.
Crossref
Crossref
Satoru Takahashi, Yuji Mishima, Kentaro Kuroishi & Masashi Ukai. (2021)
Efficacy of mirabegron, a β
3
‐adrenoreceptor agonist, in Japanese women with overactive bladder and either urgency urinary incontinence or mixed urinary incontinence: Post‐hoc analysis of pooled data from two randomized, placebo‐controlled, double‐blind studies
. International Journal of Urology 29:1, pages 7-15.
Crossref
Crossref
Marine Tournissac, Tra-My Vu, Nika Vrabic, Clara Hozer, Cyntia Tremblay, Koralie Mélançon, Emmanuel Planel, Fabien Pifferi & Frédéric Calon. (2021) Repurposing beta-3 adrenergic receptor agonists for Alzheimer’s disease: beneficial effects in a mouse model. Alzheimer's Research & Therapy 13:1.
Crossref
Crossref
Marine Tournissac, Manon Leclerc, Josue Valentin-Escalera, Milène Vandal, Cristina R. Bosoi, Emmanuel Planel & Frédéric Calon. (2021) Metabolic determinants of Alzheimer’s disease: A focus on thermoregulation. Ageing Research Reviews 72, pages 101462.
Crossref
Crossref
Kevin V. Carlson, Eric S. Rovner, Kavita V. Nair, Anna S. Deal, Rita M. Kristy & John C. Hairston. (2021)
Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the
PERSPECTIVE
registry study
. LUTS: Lower Urinary Tract Symptoms 13:4, pages 425-434.
Crossref
Crossref
Takao Katoh, Hidehiro Kakizaki, Kyu‐Sung Lee, Kota Ishida, Daisuke Katou, Osamu Yamamoto, Jar Jar Jong, Budiwan Sumarsono, Satoshi Uno & Osamu Yamaguchi. (2020)
Cardiovascular safety of mirabegron add‐on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: A post hoc analysis from the
MATCH
study
. LUTS: Lower Urinary Tract Symptoms 13:1, pages 98-107.
Crossref
Crossref
Abdulmecit Yavuz, Muhammet F. Kilinc, Mustafa Aydin, Yilmaz Ofluoglu & Göksel Bayar. (2020) Does tamsulosin or mirabegron improve ureteral stent‐related symptoms? A prospective placebo‐controlled study. LUTS: Lower Urinary Tract Symptoms 13:1, pages 17-21.
Crossref
Crossref
Cora Fogaing, Abubakr H. Mossa & Lysanne Campeau. (2020) Are Beta 3 Adrenergic Agonists Now the Preferred Pharmacologic Management of Overactive Bladder?. Current Urology Reports 21:12.
Crossref
Crossref
Yeon Joo Kim, Bum Sik Tae & Jae Hyun Bae. (2020) Cognitive Function and Urologic Medications for Lower Urinary Tract Symptoms. International Neurourology Journal 24:3, pages 231-240.
Crossref
Crossref
Chiung-Kun Huang, Chih-Chieh Lin & Alex Tong-Long Lin. (2020) Effectiveness of antimuscarinics and a beta-3 adrenoceptor agonist in patients with overactive bladder in a real-world setting. Scientific Reports 10:1.
Crossref
Crossref
Hidehiro Kakizaki, Kyu-Sung Lee, Osamu Yamamoto, Jar Jar Jong, Daisuke Katou, Budiwan Sumarsono, Satoshi Uno & Osamu Yamaguchi. (2020) Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH). European Urology Focus 6:4, pages 729-737.
Crossref
Crossref
Bahareh Vahabi, Rita Jabr, Chris Fry, Karen McCloskey, Karel Everaert, Christina W. Agudelo, Thomas F. Monaghan, Mohammad S. Rahnama'i, Jalesh N. Panicker & Jeffrey P. Weiss. (2020) ICI‐RS 2019 nocturia think tank: How can experimental science guide us in understanding the pathophysiology of nocturia?. Neurourology and Urodynamics 39:S3.
Crossref
Crossref
Yu-Wei Chang, Tsia-Shu Lo, Hsin-Ning Chang, Yi-Hsien Shiao & Yuan-Chieh Yeh. (2020) Laser Acupuncture Alleviates Symptoms and Improves Quality of Life in Women with Overactive Bladder: A Double-Blind, Pilot Randomized Controlled Trial. Evidence-Based Complementary and Alternative Medicine 2020, pages 1-11.
Crossref
Crossref
Adrian Wagg, David Staskin, Eli Engel, Sender Herschorn, Rita M. Kristy & Carol R. Schermer. (2020) Efficacy, safety, and tolerability of mirabegron in patients aged ≥65 yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR). European Urology 77:2, pages 211-220.
Crossref
Crossref
Shunye Su, Jinlei Lin, Liqin Liang, Ludong Liu, Zhipeng Chen & Yuan Gao. (2020) The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy. Medicine 99:4, pages e18802.
Crossref
Crossref
Christopher R. Chapple, Francisco Cruz, Linda Cardozo, David Staskin, Sender Herschorn, Nurul Choudhury, Matthias Stoelzel, John Heesakkers & Emad Siddiqui. (2020) Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo. European Urology 77:1, pages 119-128.
Crossref
Crossref
Andreas WiedemannAndreas Wiedemann. 2020. Geriatrische Urologie. Geriatrische Urologie
57
76
.
Sophina Bauer & Lukas Lusuardi. (2019) Therapie der überaktiven BlaseTreatment of overactive bladder. Journal für Urologie und Urogynäkologie/Österreich 26:3, pages 92-97.
Crossref
Crossref
Claudia Carrarini, Mirella Russo, Fedele Dono, Martina Di Pietro, Marianna G. Rispoli, Vincenzo Di Stefano, Laura Ferri, Filomena Barbone, Michela Vitale, Astrid Thomas, Stefano Luca Sensi, Marco Onofrj & Laura Bonanni. (2019) A Stage-Based Approach to Therapy in Parkinson’s Disease. Biomolecules 9:8, pages 388.
Crossref
Crossref
Kevin V. Carlson, Eric S. Rovner, Kavita V. Nair, Anna S. Deal, Rita M. Kristy & Carol R. Schermer. (2019) Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE). Advances in Therapy 36:8, pages 1906-1921.
Crossref
Crossref
Masaki Yoshida, Yumiko Nozawa, Daisuke Kato, Hiromi Tabuchi & Kentarou Kuroishi. (2019) Safety and effectiveness of mirabegron in patients with overactive bladder aged ≥75 years: Analysis of a Japanese post-marketing study. LUTS: Lower Urinary Tract Symptoms 11:1, pages 30-38.
Crossref
Crossref
Daisuke Kato, Hiromi Tabuchi & Satoshi Uno. (2019)
Safety, efficacy, and persistence of long-term mirabegron treatment for overactive bladder in the daily clinical setting:
I
nterim (1-year) report from a Japanese post-marketing surveillance study
. LUTS: Lower Urinary Tract Symptoms 11:1, pages 14-23.
Crossref
Crossref
Bum Sik Tae, Seok Cho, Byung Jo Jeon, Hoon Choi, Jae Young Park, Sung Yong Cho, Keon-Cheol Lee & Jae Hyun Bae. (2018) Does mirabegron relieve ureteric stent-related discomfort? A prospective, randomized, multicentre study. BJU International 122:5, pages 866-872.
Crossref
Crossref
William B. White, Emad Siddiqui, Tri Tat, Billy Franks & Carol R. Schermer. (2018) Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome. Journal of the American Society of Hypertension 12:11, pages 768-778.e1.
Crossref
Crossref
Eric S. Rovner, Kevin V. Carlson, Anna S. Deal, Kavita V. Nair, Eva E. Oakkar, Julie Park, Eric Gemmen, Rita M. Kristy, Katherine L. Gooch & Carol R. Schermer. (2018) A Prospective, non-intErventional Registry Study of PatiEnts initiating a Course of drug Therapy for overactIVE bladder (PERSPECTIVE): Rationale, design, and methodology. Contemporary Clinical Trials 70, pages 83-87.
Crossref
Crossref
Emma D. Deeks. (2018) Mirabegron: A Review in Overactive Bladder Syndrome. Drugs 78:8, pages 833-844.
Crossref
Crossref
R.K.C. Loh, B.A. Kingwell & A.L. Carey. (2017) Human brown adipose tissue as a target for obesity management; beyond cold-induced thermogenesis. Obesity Reviews 18:11, pages 1227-1242.
Crossref
Crossref
Kwang Jin KoChung Un LeeKyu-Sung Lee. (2017) Clinical implications of underactive bladder. Investigative and Clinical Urology 58:Suppl 2, pages S75.
Crossref
Crossref